

Figure 2 Flowchart for selection of studies.

References

Harrer, M., Cuijpers, P., Furukawa, T. A., & Ebert, D. D. (2021). Doing Meta Analysis in R/metareg.html, [3] Borenstien, M., Hedges, L., Higgins, J. P., & Rothstein, H. (2009). Converting among effect sizes. In Introduction to meta-analysis. John Wiley & Source Science ttps://www.meta-analysis.com/downloads/Meta-analysis%20Converting%20among%20effect%20sizes.pdf, [4] Egger, M., Davey Smith, G., Schneider, M., Winder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.), 315(7109), 629-634. https://doi.org/10.1136/bmj.315.7109.629, [5] Jaoude, S. A., Peyre, M., Degos, V., Goutagny, S., Parfait, B., & Kalamarides, M. (2020). Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. *Journal of Neurosurgery*, [6] Jaoude, S. A., Peyre, M., Degos, V., Goutagny, S., Parfait, B., & Kalamarides, M. (2020). Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. *Journal of Neurosurgery*, [2] Jaoude, S. A., Peyre, M., Degos, V., Goutagny, S., Parfait, B., & Kalamarides, M. (2020). Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. *Journal of Neurosurgery*, [4] Egger, M., Degos, V., Goutagny, S., Parfait, B., & Kalamarides, M. (2020). Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. *Journal of Neurosurgery*, [4] Egger, M., Degos, V., Goutagny, S., Parfait, B., & Kalamarides, M. (2020). Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. *Journal of Neurosurgery*, [4] Egger, M., Degos, V., Goutagny, S., Parfait, B., & Kalamarides, M. (2020). Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatogra 134(5), 1377–1385. https://doi.org/10.3171/2020.3.JNS192382, [6] Oya, S., Kim, S.-H., Sade, B., & Lee, J. H., Cho, Y. H., & Kim, C. J. (2017). A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. Journal of Neurosurgery, 114(5), 1250–1256. https://doi.org/10.3171/2020.3.JNS192382, [6] Oya, S., Kim, Y.-H., Lee, J. H. (2011). The natural history of intracranial meningiomas: Clinical article. Journal of Neurosurgery, 114(5), 1250–1256. https://doi.org/10.3171/2010.12.JNS101623, [7] Haidich, A. B. (2010). Meta-analysis in medical research. Hippokratia, 14(Suppl 1), 29–37., [8] Lee, E. J., Kim, Y.-H., Lee, J. K., Hong, S. H., Cho, Y. H., & Kim, C. J. (2017). A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. Journal of Neurosurgery, 114(5), 1250–1256. https://doi.org/10.3171/2010.12.JNS101623, [7] Haidich, A. B. (2010). Meta-analysis in medical research. Hippokratia, 14(Suppl 1), 29–37., [8] Lee, E. J., Kim, Y.-H., Lee, J. K., Hong, S. H., Cho, Y. H., & Kim, C. J. (2017). A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. Journal of Neurosurgery, 114(5), 1250–1256. https://doi.org/10.3171/2010.12.JNS101623, [7] Haidich, A. B. (2010). Discrete for estimating the risk of rapid growth in untreated intracranial meningiomas. Journal of Neurosurgery, 114(5), 1250–1256. https://doi.org/10.3171/2010.12.JNS101623, [7] Haidich, A. B. (2010). Discrete for estimating the risk of rapid growth in untreated intracranial meningiomas. Journal of Neurosurgery, 114(5), 1250–1256. https://doi.org/10.3171/2010.12.JNS101623, [7] Haidich, A. B. (2017). A novel weighted scoring system for estimating the risk of rapid growth in untreated intracranial meningiomas. Journal of Neurosurgery, 114(5), 1250–1256. https://doi.org/10.3171/2010.12.JNS101623, [7] Haidich, A. B. (2017). A novel weighted scoring system for estimating the risk of rapid growth, I. H., I. H., I. H of Neurosurgery, 127(5), 971–980. https://doi.org/10.3171/2016.9.JNS161669, [9] Shou, H., Wang, B., Vang, R., Vang, R., Vang, R. (2016). A Drug-Free Tumor Therapy Strategy: Cancer Diagnosis and Therapy. ChemMedChem, 17(4), e202100339. [11] Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011). 1002/anie.201601364, [11] Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011). 1002/anie.201601364, [11] Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011). Corticosteroids in brain cancer patients: Benefits and pitfalls. Expert Review of Clinical Pharmacology, 4(2), 233–242. https://doi.org/10.1586/ecp.11.1'

confidence interval. (*) Indicates studies with Neurofibromatosis type 2 data.